kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
1,324
JPY
+19
(+1.46%)
Dec 12, 3:30 pm JST
8.49
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
16.9
PBR
0.75
Yield
3.02%
Margin Trading Ratio
57.10
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
1,330 JPY 8.55 USD
Previous Close Dec 11
1,305 JPY 8.36 USD
High Dec 12, 9:39 am
1,333 JPY 8.56 USD
Low Dec 12, 12:45 pm
1,312 JPY 8.42 USD
Volume
62,300
Trading Value
0.08B JPY 0.53M USD
VWAP
1323.29 JPY 8.49 USD
Minimum Trading Value
132,400 JPY 849 USD
Market Cap
0.04T JPY 0.26B USD
Number of Trades
193
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
225
1-Year High Jul 14, 2025
1,532
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 24,600 41,400 1.68
Nov 28, 2025 33,900 37,000 1.09
Nov 21, 2025 35,300 38,800 1.10
Nov 14, 2025 23,500 40,400 1.72
Nov 7, 2025 22,700 45,100 1.99
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.